Schwartz et al. proposed an oncogenic role for HNF4α in CRC by combining the use of HNF4α antagonists of the MEDICA family and siRNA-mediated inhibition of HNF4α in CRC cell lines [161]. This evidence concerns the gene HNF4A and colorectal carcinoma.